Антифосфолипидный синдром - часть 60

245

temic lupus erythematosus. Ann Rheum Dis 1988;
47: 286—290.

55. Tsutsumi A, Koike T, Ichikawa K, et al. IgG

subclass distribution of anticardiolipin antibody
in patients with systemic lupus erythematosus. J
Rheumatology 1988; 15: 1764—1767.

56. Loizou S, Cofiner C, Weetman AP, Walport

MJ. Immunoglobulin class and IgG subclass dis
tribution of anticardiolipin antibodies in patients
with systemic lupus erythematosus and associated
disorders. Clin Exp Immunol 1992; 90: 434—
439. 

57. Samaritano LR, Ng S, Sobel R, et al.

Anticardiolipin IgG subclass. Association of IgG2
with arterial and/or venous thrombosis. Arthritis
Rheum 1997; 40: 1998—2006.

58. Samarkos M, Davies KA, Gordon C, et al.

IgG subclass distribution of antibodies against 

β

2



GPI and cardiolipin in patients with systemic
lupus erythematosus and primary antiphospho
lipid syndrome, and their clinical associations.
Rheumatology 2001; 40: 1026—1032. 

59. Arvieux J, Roussel B, Ponard D, Colomb

MG. IgG2 subclass resriction of anti

β

2

glycopro

tein I antibodies in autoimmune patients. Clin
Exp Immunol 1994; 95: 310—315.

60. Arveux J, Darnige L, Caron C, et al. Deve

lopment of an ELISA for autoantibodies to pro
thrombin showing their orevalence in patients
with lupus anticoagulant. Thromb Haemost 1995;
74: 1120—1125.

61. Galli M, Beretta G, Daldossi M, et al.

Different anticoagulant and immunological prop
erties anf antiprothrombin antibodies in patients
with antiphospholipid antibodies. 1997; 77: 486—
491.

62. Amengual O, Atsuni T, Koike T. Specifi

cities, properties, and clinical significance of
antiprothrombin antibodies. Arthritis Rheum
2003; 48: 886—895.

63. Galli M, Barbui T. Antiprothrombin anti

bodies: detection and clinical significance. Blood
1999; 93: 2149—2157.

64. Horbach D, van Oort E, Derksen R, de

Groot P. The contribution of antiprothrombin
antibodies to lupus anticoagulant activity  dis
crimination between functional and nonfunc
tional antiprothrombinantibodies. Thromb
Haemost 1998; 79: 790—5.

65. Akimoto T, Akama T, Kono I, Sumida T.

Relationship between clinical feature and binding
domains of antiprothrombon autoantibodies in
patients with systemic lupus erythematosus and
antiphospholipid syndrome. Lupus 1999; 8:
761—766.

66. Nojima J, Kuratsune H, Suehisa E, et al.

Association between the prevalence of antibodies
to 

β

2

glycoproteinI, prothrombin, protein C,

protein S, and annexin V in patients with systemic
lupus erythematosus anr thrombotic and throm
bocytopenic complications. Clin Chem 2001; 47:
1008—1015.

67. Love PE, Santoro SA. Antiphospholipid

antibodies: Anticardiolipin and the lupus antico
agulant in systemic lupus erythematosus (SLE)
and nonSLE disorders. Ann Intern Med 1990;
112: 682.

68. AbuShakra, M, Gladman, D, Urowitz,

MB, Farewell, V. Anticardiolipin antibodies in
systemic lupus erythematosus: Clinical and labo
ratory correlations. Am J Med 1995; 99: 624.

69. Sebastiani GD, Galeazzi M, Tincani A, et

al. Anticardiolipin and antibeta2GPI antibodies
in a large series of European patients with sys
temic lupus erythematosus. Prevalence and clini
cal associations. European Concerted Action on
the Immunogenetics of SLE. Scand J Rheumatol
1999; 28: 344.

70. Nasonov EL, Kovalev VYu, Alekberova

ZS, Soloviev SK. Prediction of thrombosis in
patients with systemic lupus erythematosus: the
role of antibodies to cardiolipin. Sov Arch Intern
Med 1992; 64: 348—353.

71. Neville C, Rauch J, Kassis J, et al.

Thrombotic risk in partients with high titre anti
cardiolipin and multiple antibodies. Thromb
Haemost 2003; 90: 108.

72. Cervera R, Piette JC, Font J, et al.

Antiphospholipid syndrome: clinical and immu
nologic manifestations and patterns of disease
expression in a cohort of 1,000 patients. Arthritis
Rheum 2002; 46: 1019.

73. Galli M, Luciani D, Bertolini G, Barbui

T. Lupus anticoagulant are stronger risk factor
for thrombosis than anticatdiolipin antibodies in
the antiphospholipid syndrome: a systematic
review of the literature. Blood 2003; 101:
1827—1832.

ГЛАВА 8. Клиническое значение антифосфолипидных антител

Насонов Е.Л. Антифосфолипидный синдром

246

74. Александрова ЕН, Новиков АА, Решет

няк ТМ, Клюквина НГ, Решетняк ДВ, Насо
нов Е.Л. Антитела к 

β

2

ГП1 и антитела к

кардиолипину при антифосфолипидном синд
роме: анализ чувствительности и специфич
ности. Клин. медицина, 2003; 9: 25—31.

75. Amengual O, Atsumi T, Khamashta MA,

Koike T, Huges GRV. Specificity of ELISA for
antibody to 

β

2

glicoprotein I in patients with

antiphospholipid sindrome. Br J Rheumatol 1996;
35: 1239—1243.

76. Carreras LO, Forastiero RR, Martinuzzo

ME. Which are the best biological markers of the
antiphospholipid syndrome? J Autoimmunity
2000; 15: 163—172.

77. Решетняк ТМ, Дерксен РВ, Алекберова

ЗС, и др. Антитела к 

β

2

гликопртеину I при

системной красной волчанке: новый лаборо
торный маркер антифосфолипидного синдро
ма. Клин. медицина, 1998; 3: 36—40.

78. Martinuzzo ME, Forastiero RR, Carreras

LO. Anti 

β

2

glycoprotein I antibodies: detection

and association with trombosis Br J Haematol
1995; 89: 397—405.

79. GomezPacheco L, Villa AR, Drencard C,

Cabiedes J, Cabral AR, AlarconSegovia D.
Serum anti

β

2

glycoprotein I and anticardiolipin

antibodies during trombosis in systemic lupus ery
tematosus patients. Am J Med 1999; 106: 417—
423.

80. Long AA, Ginsberg JS, BrillEdwards P,

Johnston M, Turner C, Deuburg JA, Bensen WG,
Cividino A, Andrew M, Hirsh J. The realation
ship of antiphospholipid antibodies to throm
boembolic disease in systemic lupus erytematosus:
a crosssectional study. Thromb Haemost 1991;
66: 520—525.

81. Wahl DG, Guillemin F, de Maistre E, Peret

C., Lecompte T, Thibaut G. Risk for venous
thrombosis related to antiphospholipid antibodies
in systemic lupus erythematosusA metaanalisis.
Lupus 1997; 6: 464—473.

82. Roubey RAS, Maldonado MA, Byrd SN.

Comparison of an enzimelinked immunosorbent
assay for antibodies to 

β

2

glycoprotein I and a

conventional anticardiolipin immunoassay.
Arthritis Rheum 1996; 39: 1606—1607.

83. Detkova D, GilAguado A, Lavilla P et al.

Do antibodies to 

β

2

glycoprotein I contribute to

the better characterization of the antiphospholipid
syndrome? Lupus 1999; 8: 430438.

84. Harris EN, Pierangeli SS, Gharavi AE.

Diagnosis of the antiphospholipid syndrome a
proposal for use of laboratory tests. Lupus 1998;
7(Suppl); S.144—148.

85. Najmey SS, Keil B, Adib DY, De Bary VA.

The association of antibodies to 

β

2

glicoprotein I

with the antiphospholipid syndrome: A Meta
analysis. Ann Clin Lab Science 1997; 27: 41—46

86. Cabiedes J, Cabral A, AlarconSegovia D.

Clinical manifestation of the antiphospholipid
syndrome in patients with systemic lupus erytem
atosus associate more strongly with anti

β

2

glyco

proteinI than with antiphospholipid antibodies. J
Rheumatol 1995; 22: 1899—1906.

87. Picillo U, Marcilis MR, Italiano G. Anti

bodies to 

β

2

glycoprotein I in anticardiolipin neg

ative patients. J Rheumatol 1998; 25: 1440—
1442.

88. Loizou S, Byron MA, Englert HJ, et al.

Association of quantitative anticardiolipin anti
body levels with fetal loss and time of loss in sys
temic lupus erythematosus. Q J Med 1988;
68:525

89. Geis W, Branch DW. Obstetric implications

of antiphospholipid antibodies: pregnancy loss
and other complications. Clin Obstet Gynecol
2001; 44: 2.

90. Lockwood CJ, Schur PH. Clinical manifes

tations and diagnosis of the antiphospholipid syn
drome in pregnancy UpToDate 2003; 11.3.

91. Oshiro BT, Silver RM, Scott JR, et al.

Antiphospholipid antibodies and fetal death.
Obstet Gynecol 1996; 87: 489.

92. Kupferminc MJ. Thrombophilia and preg

nancy. Reproductive Biol Endocrinol 2003; 1:
111.

93. Branch DW, Scott JR, Kochenour NK, et

al. Obstetric complications associated with the
lupus anticoagulant. N Engl J Med 1985; 313:
1322.

94. Branch DW, Khamashta MA. Antiphos

pholipid syndrome: obstetric diagnosis, manage
ment, and controversies. Obstet Gynecol 2003;
101: 1333.

95. Lynch A, Byers T, Emlen W, et al. Associ

ation of antibodies to beta(2)glycoprotein 1 with
pregnancy loss and pregnancyinduced hyperten

247

sion: A prospective study in lowrisk pregnancy.
Obstet Gynecol 1999; 93: 193.

96. Lee RM, Emlen, W, Scott, JR, et al. Anti

beta2glycoprotein I antibodies in women with
recurrent spontaneous abortion, unexplained fetal
death, and antiphospholipid syndrome. Am J
Obstet Gynecol 1999; 181: 642.

97. Yasuda M, Takakuwa, K, Tokunaga, A,

Tanaka, K. Prospective studies of the association
between anticardiolipin antibody and outcome of
pregnancy. Obstet Gynecol 1995; 86: 555.

98. Lima F, Khamashta MA, Buchanan, NM,

et al. A study of sixty pregnancies in patients with
the antiphospholipid syndrome. Clin Exp Rheu
matol 1996; 14:131.

99. Branch DW, Silver, RM Blackwell, JL, et

al. Outcome of treated pregnancies in women with
antiphospholipid syndrome: an update of the Utah
experience. Obstet Gynecol 1992; 80: 614.

100. Schei, B, Ostensen, M, Moen, T, et al.

Can maternal antiphospholipid antibodies predict
the birth of a smallforgestational age child?
Acta Obstet Gynecol Scand 1995; 74: 425.

101. Out HJ, Bruinse HW, Christiaens GC, et

al. A prospective, controlled multicenter study on
the obstetric risks of pregnant women with
antiphospholipid antibodies. Am J Obstet Gynecol
1992; 167: 26.

102. Montaruli B, Borchiellini A, Tamponi G,

et al. Factor V Arg506>Gln mutation in patients
with antiphospholipid antibodies. Lupus 1996; 5:
303.

103. Silver RM, Draper ML, Scott JR, et al.

Clinical consequences of antiphospholipid anti
bodies: An historic cohort study. Obstet Gynecol
1994; 83: 372.

104. Lynch A, Marlar R, Murphy J, et al. Anti

phospholipid antibodies in predicting adverse
pregnancy outcome. A prospective study. Ann
Intern Med 1994; 120: 470.

105. Pattison NS, Chamley LW, McKay EJ, et

al. Antiphospholipid antibodies in pregnancy:
prevalence and clinical associations. Br J Obstet
Gynaecol 1993; 100: 909.

106. Alsulyman OM, Castro, MA, Zuckerman,

E, et al. Preeclampsia and liver infarction in
early pregnancy associated with the antiphos
pholipid syndrome. Obstet Gynecol 1996; 88:
644.

107. Branch DW, Porter TF, Rittenhouse L, et al.

Antiphospholipid antibodies in women at risk for
preeclampsia. Am J Obstet Gynecol 2001; 184: 825.

108. American College of Obstetricians and

Gynecologists. Antiphospholipid syndrome.
ACOG educational bulletin 244. ACOG 1998;
Washington, DC.

109. Galli M. Should we include antipro

thrombin antibodies in the screening for the
antiphospholipid syndrome? J Autoimmun 2000;
15: 101—105.

110. Puurunen M, Vaarala O, Julkunen H,

Aho K, Palosuo T. Antibodies to phospholipid
binding plasma proteins and occurrence of
thrombosis in patients with systemic lupus ery
thematosus. Clin Immunol Immunopathol 1996;
80: 16—22.

111. D'Angelo A, Safa O, Crippa L, Garlando

A, Sabbadini M, Vigano' D'Angelo S.
Relationship of lupus anticoagulant, anticardi
olipin, antibeta2GPI and antiprothrombin
autoantibodies with history of thrombosis in
patients with the clinical suspicion of APA syn
drome. Thromb Haemost 1997; 78: 967—8.

112. Galli M, Beretta G, Daldossi M, Bevers

EM, Barbui T. Different anticoagulant and
immunological properties of antiprothrombin
antibodies in patients with antiphospholipid anti
bodies. Thromb Haemost 1997; 77: 486—91.

113. Swadzba J, De Clerck L, Stevens W,

Bridts C, van Cotthem K, Musial J, et al. Anti
cardiolipin, antibeta(2)glycoprotein I, antipro
thrombin antibodies, and lupus anticoagulant in
patients with systemic lupus erythematosus with a
history of thrombosis. J Rheumatol 1997; 24:
1710—5.

114. Bertolaccini M, Atsumi T, Khamashta M,

Amengual O, Hughes G. Autoantibodies to human
prothrombin and clinical manifestations in 207
patients with systemic lupus erythematosus. J
Rheumatol 1998; 25: 1104—8.

115. Guerin J, Smith O, White B, Sweetman G,

Feighery C, Jackson J. Antibodies to prothrombin
in antiphospholipid syndrome and inflammatory
disorders. Br J Haematol 1998; 102: 896—902.

116. Inanc M, Donohoe S, Ravirajan C,

RadwayBright E, Mackie I, Machin S, et al.
Antibeta2glycoprotein I, anti prothrombin and
anticardiolipin antibodies in a longitudinal study

ГЛАВА 8. Клиническое значение антифосфолипидных антител

Насонов Е.Л. Антифосфолипидный синдром

248

of patients with systemic lupus erythematosus and
the antiphospholipid syndrome. Br J Rheumatol
1998; 37: 1089—94.

117. Sorice M, Pittoni V, Circella A, et al. Anti

prothrombin but not pure anticardiolipin antibod
ies are associated with the clinical features of the
antiphospholipid antibodies syndrome. Thromb
Haemost 1998; 80: 713—715.

118. Lakos G, Kiss E, Regeczy N, et al. Anti

prothrombin and antiannexin V antibodies imply
risk of thrombosis in patients with systemic
autoimmune disease. J Rheumatol 2000; 27:
924—929.

119. MunozRodriguez F, Reverter J, Font J, et

al. Prevalence and clinical significance of
antiprothrombin antibodies in patients with sys
temic lupus erythematosus or with primary
antiphospholipid syndrome. Haematologica
2000; 85: 632—637.

120. Nojima J, Kuratsune H, Suehisa E, et al.

Antiprothrombin antibodies combined with lupus

anticoagulant activity is an assensial risk factor
for venous thromboembolism in patients with sys
temic lupus erythematosus. Br J Haematol 2001;
114: 647—654.

121. Atsumi T, Ieko M, Bertolaccini ML, et al.

Association of autoantibodies against the phos
phatidylserineprothrombin complex with mani
festations of the antiphospholipid syndrome and
with the oresence of lupus anticoagulant. Arthritis
Rheum 2000; 43: 1982—1983.

122. Калашникова ЛА, Чапман Н, Насонов

ЕЛ, и соавт. Новые клинические имммуноло
гические данные о синдроме Снеддона. Клин.
медицина, 1998; 6: 34—37.

123. Gris JC, Quere I, Sanmarco M, et al.

Antiphospholipid and antiprotein syndromes in
nonthrombotic, nonautoimmune women with
unexplained recurrent primary early foetal loss.
The Nimes Obstretricians and Haematologist
Study — NOHA. Thrombo Haemost 2000; 84:
228—236.